1: Retina. 2012 Jan 31; [Epub ahead of print] 

Correspondence.

Romano MR, Pastora-Salvador N, Vallejo-Garcia JL.

*Department of Ophthalmology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
daggerDepartment of Ophthalmology, Universitary Hospital La Paz, Madrid, Spain.

PMID: 22298016  [PubMed - as supplied by publisher]

2: Retina. 2012 Jan 31; [Epub ahead of print] 

A Spectral-Domain Optical Coherence Tomography Description of ND: YAG Laser
Hyaloidotomy in Premacular Subhyaloid Hemorrhage.

Pichi F, Ciardella AP, Torrazza C, Morara M, Scano G, Mattana G, Nucci P.

*San Giuseppe Hospital - Univeristy Eye Clinic, Milan, Italy daggerPoliclinico
Sant'Orsola-Malpighi - Ophthalmology Unit, Bologna, Italy double daggerClinica
Madonna del Rimedio - Ophthalmology Unit, Oristano, Italy.

PMID: 22298015  [PubMed - as supplied by publisher]

3: Retina. 2012 Jan 31; [Epub ahead of print] 

OPTIMIZING INDIVIDUALIZED THERAPY WITH BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED
MACULAR DEGENERATION.

Patel PJ, Tufail A; for the ABC Trial Investigators.

NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and
UCL Institute of Ophthalmology, London, United Kingdom.

PURPOSE: The purpose of this study was to evaluate a standardized retreatment
strategy with intravitreal bevacizumab in the treatment of neovascular
age-related macular degeneration. METHODS: In this double-masked randomized
trial, patients with neovascular age-related macular degeneration were
randomized to intravitreous bevacizumab or standard care. Bevacizumab treatment
was given at 6 weekly intervals with 3 consecutive injections (loading phase)
followed by variable dosing to Week 54 using standardized retreatment criteria.
RESULTS: Three hundred and eighty retreatment decisions were made after 3 fixed
injections for 64 patients randomized to bevacizumab that completed 1-year
follow-up. The most common criterion for retreatment was persistent intraretinal
fluid on optical coherence tomography imaging, and fluorescein angiography did
not drive any retreatment decision. The mean (median) change in visual acuity
and optical coherence tomography central macular thickness after the 3 loading
treatments to Week 54 was +0.4 (+1.0) letters and +2.0 (+1.0) mum, respectively,
with a mean (median) of 7.1 (7.0) injections. The median time to retreatment was
42 days with 12 of 69 injection-free episodes (17%) lasting more than 3 months.
CONCLUSION: Sustained improvements in structure and function were achieved using
this 6 weekly variable-dosing regimen with intravitreal bevacizumab. Most
retreatment decisions were based on qualitative interpretation of optical
coherence tomography scans.

PMID: 22298014  [PubMed - as supplied by publisher]

4: Retina. 2012 Jan 31; [Epub ahead of print] 

ANATOMICAL AND VISUAL RESULTS OF TRANSCONJUNCTIVAL SUTURELES VITRECTOMY USING
SUBCONJUNCTIVAL ANESTHESIA PERFORMED ON SELECT PATIENTS TAKING ANTICOAGULANT AND
ANTIPLATELET AGENTS.

Malik AI, Foster RE, Correa ZM, Petersen MR, Miller DM, Riemann CD.

Cincinnati Eye Institute, University of Cincinnati, Cincinnati, Ohio.

PURPOSE: The purpose of this study was to report the observed outcomes of
anticoagulated patients undergoing transconjunctival sutureless vitrectomies
using subconjunctival anesthesia without preoperative cessation of
anticoagulation and antiplatelet (AC/AP) agents. METHODS: A retrospective chart
review was performed on patients taking AC/AP agents who were undergoing
transconjunctival sutureless vitrectomies with subconjunctival anesthesia
between January 2007 and June 2009. Intra- and postoperative complications (such
as massive hemorrhage), anatomical results, satisfactory analgesia (informed by
patients and recorded by surgeon), anatomical results, and visual acuity were
documented. RESULTS: Sixty-three surgeries were performed on 56 eyes of 52
patients. Thirty-two patients were taking aspirin and clopidogrel, 18 were
taking warfarin, 5 were taking clopidogrel, 3 were taking aspirin and warfarin,
2 were taking acetylsalicylic acid and dipyridamole, and 1 was taking warfarin
and clopidogrel. All patients had satisfactory analgesia. No intraoperative
complications occurred. Seven eyes (13%) had postoperative vitreous hemorrhage.
Overall, 79% of patients had improved postoperative visual acuity, 16% of
patients had unchanged visual acuity, and 5% of patients had worse visual acuity
at last follow-up visit. CONCLUSION: Medical disease requiring systemic AC/AP
therapy is often present in patients with vitreoretinal disease.
Transconjunctival sutureless vitrectomies using subconjunctival anesthesia may
be a safe and effective surgical option in select patients in whom cessation of
AC/AP and/or delayed ophthalmic intervention is imprudent.

PMID: 22298013  [PubMed - as supplied by publisher]

5: Retina. 2012 Jan 31; [Epub ahead of print] 

FACTORS DETERMINING VISUAL OUTCOME IN ENDOGENOUS CANDIDA ENDOPHTHALMITIS.

Sallam A, Taylor SR, Khan A, McCluskey P, Lynn WA, Manku K, Pacheco PA, Lightman
S.

*Moorfields Eye Hospital, London, UK daggerUCL Institute of Ophthalmology,
London, UK double daggerDepartment of Ophthalmology, Royal Prince Alfred
Hospital, Sydney, Australia  section signDepartment of Infection and Immunity,
Ealing Hospital, Middlesex, UK.  paragraph signSave Sight Institute, Sydney
Medical School, University of Sydney, Sydney, Australia.

PURPOSE: To determine factors affecting the visual outcome of eyes with
endogenous Candida endophthalmitis. METHODS: Retrospective cohort study of 44
eyes from 36 patients diagnosed with candida endophthalmitis at 2 tertiary
referral uveitis centers. Outcome measures included the development of retinal
detachment and the occurrence of visual loss (visual acuity of <20/40) and
severe visual loss (visual acuity of PMID: 22298012  [PubMed - as supplied by publisher]

6: Retina. 2012 Jan 27; [Epub ahead of print] 

INTRAVITREAL SALINE INJECTION AMELIORATES LASER-INDUCED RETINAL DAMAGE IN RATS.

Belokopytov M, Shulman S, Dubinsky G, Belkin M, Rosner M.

*Goldschleger Eye Research Institute, Sackler School of Medicine, Tel Aviv
University, Sheba Medical Center, Tel Hashomer, Israel daggerDepartment of
Ophthalmology, Sapir Medical Center, Kfar Saba, Israel.

PURPOSE: Injury to the central nervous system has been shown to trigger a
physiologic response in the form of some degree of natural self-repair. This
beneficial reaction may be boosted by appropriate preconditioning via a
reversible injury to the retina. Here we report the ameliorative effect of
intravitreal saline injection on laser-induced retinal damage. METHODS: Standard
argon laser lesions (514 and 544 nm, 200 mum, 0.1 W, 0.05 seconds) were induced
in the eyes of 36 Dark Agouti pigmented rats and immediately followed by
injection of saline either intravitreally (5 muL) or intravenously (0.5 mL).
Lesions were evaluated histologically and morphometrically after 3, 20, and 60
days. RESULTS: At all 3 time points, the eyes of rats injected intravitreally
showed less laser-induced retinal cell loss (P < 0.05) and smaller lesion
diameters (P < 0.05) than those of intravenously injected rats. CONCLUSION:
Intravitreal saline injection evidently has a neuroprotective effect on the rat
retina. The mechanism of action of this effect should be further elucidated and
its clinical applicability tested.

PMID: 22290081  [PubMed - as supplied by publisher]

7: Retina. 2012 Feb;32 Suppl 1:S9-S10. 

In gratitude.

Schatz H.

New York, New York.

PMID: 22270785  [PubMed - in process]

8: Retina. 2012 Feb;32 Suppl 1:S8-9. 

50 years of friendship.

Gitter KA.

Retina Associates, New Orleans, Louisiana.

PMID: 22270784  [PubMed - in process]

9: Retina. 2012 Feb;32 Suppl 1:S7. 

Four decades of friendship and fun.

Dodick JM.

Department of Ophthalmology, New York University School of Medicine, New York,
New York.

PMID: 22270783  [PubMed - in process]

10: Retina. 2012 Feb;32 Suppl 1:S4-6. 

Building of an empire.

Fisher YL, Sorenson J, Slakter JS, Spaide RS, Freund KB, Klein RW.

Vitreous Retina Macula Consultants of New York, New York, New York.

PMID: 22270782  [PubMed - in process]

11: Retina. 2012 Feb;32 Suppl 1:S27-8. 

Something about larry.

Mieler WF, Kang-Mieler JJ.

*University of Illinois Eye and Ear Infirmary, Chicago, Illinois daggerIllinois
Institute of Technology, Chicago, Illinois.

PMID: 22270781  [PubMed - in process]

12: Retina. 2012 Feb;32 Suppl 1:S26. 

Salutation to a "legend".

Agarwal A.

Vanderbilt Eye Institute, Nashville, Tennessee.

PMID: 22270780  [PubMed - in process]

13: Retina. 2012 Feb;32 Suppl 1:S26. 

Tribute to larry.

Bird A.

Institute of Ophthalmology, London, United Kingdom.

PMID: 22270779  [PubMed - in process]

14: Retina. 2012 Feb;32 Suppl 1:S25. 

Yannuzzi'S macula center alumni (ymca).

Ciardella AP.

Policlinico S. Orsola Malpighi, Bologna, Italy.

PMID: 22270778  [PubMed - in process]

15: Retina. 2012 Feb;32 Suppl 1:S24-5. 

Books, atlases, and papers.

Coleman DJ.

Weill Cornell Medical College, New York, New York.

PMID: 22270777  [PubMed - in process]

16: Retina. 2012 Feb;32 Suppl 1:S23-4. 

Band director.

Brancato R.

San Raffaele Hospital, Universita Vita e Salute, Milan, Italy.

PMID: 22270776  [PubMed - in process]

17: Retina. 2012 Feb;32 Suppl 1:S22-3. 

Latin america and larry yannuzzi.

Belfort R Jr, Farah M.

Department of Ophthalmology, Hospital Sao Paulo, Federal University of Sao
Paulo, Sao Paulo, Brazil.

PMID: 22270775  [PubMed - in process]

18: Retina. 2012 Feb;32 Suppl 1:S22. 

Tribute to lawrence a. Yannuzzi.

Shimizu K.

Gumma University, Gunman, Japan.

PMID: 22270774  [PubMed - in process]

19: Retina. 2012 Feb;32 Suppl 1:S21-2. 

Kudos.

Chang S.

Columbia University College of Physicians and Surgeons, New York, New York.

PMID: 22270773  [PubMed - in process]

20: Retina. 2012 Feb;32 Suppl 1:S21. 

Brilliant.

Chew E, Murphy RP.

*The National Eye Institute, National Institutes of Health, Bethesda, Maryland
daggerThe Retina Group of Washington, Chevy Chase, Maryland.

PMID: 22270772  [PubMed - in process]

21: Retina. 2012 Feb;32 Suppl 1:S20-1. 

Scientific giant.

Rosenfeld PJ.

Bascom Palmer Eye Institute, Miami, Florida.

PMID: 22270771  [PubMed - in process]

22: Retina. 2012 Feb;32 Suppl 1:S2-4. 

A man of many talents.

Brucker AJ.

Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania.

PMID: 22270770  [PubMed - in process]

23: Retina. 2012 Feb;32 Suppl 1:S19-20. 

Tribute to yannuzzi.

Jampol LM.

Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

PMID: 22270769  [PubMed - in process]

24: Retina. 2012 Feb;32 Suppl 1:S18-9. 

The wizard of macula:  a tribute to larry yannuzzi.

Shields J, Shields C.

Ocular Oncology Service, Wills Eye Institute, Philadelphia, Pennsylvania.

PMID: 22270768  [PubMed - in process]

25: Retina. 2012 Feb;32 Suppl 1:S17-8. 

Great physician.

Goldberg MF.

The Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.

PMID: 22270767  [PubMed - in process]

26: Retina. 2012 Feb;32 Suppl 1:S16-7. 

Joie de vivre.

Soubrane G, Coscas G.

University of Paris, Creteil, France.

PMID: 22270766  [PubMed - in process]

27: Retina. 2012 Feb;32 Suppl 1:S15-6. 

Tribute to a good friend.

Singerman LJ.

Retina Associates of Cleveland, Cleveland, Ohio.

PMID: 22270765  [PubMed - in process]

28: Retina. 2012 Feb;32 Suppl 1:S12-4. 

Tennis partners.

Flynn HW Jr, Blumenkranz MS.

*Bascom Palmer Eye Institute, Miami, Florida daggerByers Eye Institute at
Stanford, Palo Alto, California.

PMID: 22270764  [PubMed - in process]

29: Retina. 2012 Feb;32 Suppl 1:S12. 

Tribute to a friend.

Lincoff H.

New York Presbyterian Hospital, Weill Medical College of Cornell University, New
York, New York.

PMID: 22270763  [PubMed - in process]

30: Retina. 2012 Feb;32 Suppl 1:S12. 

The teacher's teacher.

Pulido JS.

Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.

PMID: 22270762  [PubMed - in process]